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Abstract: Senile dementia is a syndrome in the elderly involving deﬁ  cits in memory and 
cognition. There has been a long history of research and medical practice in dementia in China, 
during which the ancient Chinese people have formed a whole theory and accumulated abundant 
experience in the treatment of dementia. During recent decades, with new theories and tech-
nologies being digested and integrated, progress has been made in the medical and pharmacy 
research on senile dementia in China. In this review, we will focus on the traditional opinion, 
clinical practice, and recent progress in pharmacological research in China towards the treatment 
of dementia. We also discuss the potential trends of global convergence.
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The term “senile dementia” refers to a clinical syndrome seen in the elderly charac-
terized by impairment of memory and cognition. With the dramatic improvement of 
average life expectancy and the fast increasing of the aged population in recent years, 
senile dementia has become a major problem of public health.
Alzheimer’s disease (AD) is the most common type of dementia, which is a pro-
gressive neurodegenerative disease and has become the third greatest threat to elderly, 
inferior only to cardiovascular disease and cancer. Since 1907, when German surgeon 
Alois Alzheimer reported the ﬁ  rst case of dementia that now bears his name, great 
efforts have been made in attempt to discover the pathology and remedy of AD. Though 
neither consensus concerning pathogenesis nor perfect therapy is available at present, 
progress has been made. Pathological hallmarks of AD include extracellular deposition 
of senile plaques (SP), formation of intracellular neuroﬁ  brillary tangles (NFT), and 
lesions of cholinergic neurons together with synaptic alterations in cerebral cortex, 
hippocampus, and other brain regions essential for cognitive function. It is now well 
accepted that multiple factors, such as apoptosis, oxidative stress, excitotoxicity, and 
disturbance of energy metabolism homeostasis, contribute to the progression of AD. 
Another common form of dementia in the elderly is vascular dementia (VD). This 
disorder, like AD, presents as a clinical syndrome of intellectual impairment caused 
by cerebrovascular elements such as stroke, infarct, and hemorrhagic brain lesion. As 
the common downstream pathway of neurodegenerative disease, free radical damage-
induced oxidative stress and apoptosis are involved in the VD pathology.
China is well known for its long history of traditional Chinese medicine (TCM), 
which has endured for thousands of years. Through persistent attempts and practice 
for generations, Chinese people have accumulated profound experience in disease 
prevention, diagnosis, and treatment, and formed a whole theoretical system of medi-
cine and therapy. We will introduce the status and progress of dementia treatment in 
China with TCM in this review.Clinical Interventions in Aging 2007:2(2) 202
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Progress in medication research
In the vast territory of China, smart and industrious Chinese 
people have made the best of immense natural resources for 
medical application. Herbal medicines of intellective and 
memory beneﬁ  ts were mentioned in some geography litera-
ture such as Shan Hai Jing and some medical literature like 
Ben Cao Gang Mu (Compendium of Materia Medica).
Over the past years, quite a number of viewpoints have 
been put forward with the intent of explaining theories of 
TCM in how dementia forms and develops. In general, loss 
of memory was indicated to come from atrophy and empty 
state of brain rather than heart, and was classiﬁ  ed according 
to clinical symptoms. On one hand, kidney decline as well 
as blood decay results in brain dystrophy. Hence, herbal 
medicine like ginseng, fructus lycii, polygala, angelica can 
be used to supplement blood and nourish kidney. On the 
other hand, pent-up phlegm and retarded blood circulation 
can induce chaos and toxicity of brain. Accordingly, such 
herbals as glycyrrhiza, atractylodes, rhubarb, and safﬂ  ower 
often served as expectorants and promoters for blood circula-
tion. Furthermore, it was suggested that normal functioning 
of human body not only lies on the function of every single 
viscus, but, more importantly, depends on the harmony and 
balance between each apparatus. During recent decades, a 
growing numbers of preclinical and clinical studies have 
found efﬁ  ciencies of some herbal extract, some speciﬁ  c 
combinations of herbals, and herbal tea in AD treatment. 
In this review we will discuss the pharmacologic proﬁ  les of 
some representative natural products.
Huperzine A
(–)-Huperzine A (HupA) is a novel Lycopodium alkaloid iso-
lated from the Chinese medicinal herb Huperzia serrata (Qian 
Ceng Ta, Figure 1A), which has been used by Chinese civilians 
for centuries in the treatment of such conditions as contusions, 
strains, swelling, and schizophrenia. As a chemically unique 
compound in comparison with other agents under study for 
AD, namely tacrine, galanthamine, donepezil, and rivastig-
mine, HupA is a reversible, potent, and selective acetylcho-
linesterase (AChE) inhibitor, and has been found to improve 
cognitive deﬁ  cits in a broad range of animal models (Wang 
et al 2006a). Phase IV clinical trials conducted in China have 
demonstrated that HupA can signiﬁ  cantly improve memory 
of elderly people and patients with AD and VD without any 
notable side effects (Xu et al 1995; Yang et al 2003).
In vitro and in vivo studies with respect to AChE inhibi-
tion demonstrated that AChE inhibition potency of HupA is 
similar or superior to those of inhibitors currently being used 
in AD treatment (Wang et al 1986; Wang and Tang 1998; 
Ogura et al 2000; Liang and Tang 2004). Studies in our labo-
ratory showed that in cortex, hippocampus, and striatum of 
mammalian brain, HupA exerts preferential inhibition against 
G4 (10S) AChE, which is the physiologically relevant form at 
cholinergic synapses and is the major form for metabolizing 
ACh (Zhao and Tang 2002).
Changes in oxidative metabolism are thought to be 
involved in such neurodegenerative disease as AD and 
ischemia/reperfusion-induced brain injury. Accumulated 
damage of cellular structure and function from free radicals 
are thought to result in oxidative stress and be involved 
in events that lead to neurodegeneration. HupA has been 
demonstrated by recent studies in our laboratory to protect 
against H2O2- and β-amyloid (Aβ)-induced cell lesion, de-
crease the level of lipid peroxidation, increase antioxidant 
enzyme activities in rat PC12 and NG108–15 cell lines 
and primary cultured cortical neurons (Xiao et al 1999, 
2000a, 2000b, 2002; Zhang et al 2002), and protect against 
serum deprivation-induced toxicity (Zhou and Tang 2002), 
oxygen-glucose deprivation-induced toxicity (Zhou et al 
2001b, 2001c), and ischemia-induced toxicity (Zhou et al 
2001d; Wang et al 2006b), which may beneﬁ  t AD and VD 
therapy. These protective effects involve, at least in part, the 
abilities of HupA to regulate apoptosis-related genes (Zhou 
et al 2001c), upregulate NGF secretion and its down-stream 
signaling (Tang et al 2005a, 2005b; Wang et al 2006b), 
inhibit oxidative stress, and improve energy metabolism 
(Gao and Tang 2006). We also found that HupA can modu-
late the processing of amyloid precursor protein (APP) in 
both rats infused intracerebroventricularly with Aβ1–40 and 
HEK293sw cell line, via regulating protein kinase C (PKC) 
(Zhang et al 2004). This effect might be beneﬁ  cial for AD 
therapy, since it promotes the nonamyloidogenic pathway of 
APP metabolism and hence reduces the production of Aβ, 
and the nonamyloidogenic product itself, namely APPsα, is 
proved neuroprotective.
In the recent clinical trials carried out in China, HupA 
has demonstrated signiﬁ  cant effect and safety in the treat-
ment of neurodegenerative disease such as AD (Xu et al 
1995; Yang et al 2003) and vascular dementia (Wei et al 
2001; Yin et al 2001; Zhang and Fu 2001; Zhong and Liang 
2004), as well as improvement of memory and cognitive 
deﬁ  cits caused by other pathogenies, such as schizophrenia 
(Fang et al 2002; Ma et al 2003; Yang 2003), brain trauma 
(Zhou et al 2001a), and lack of iodine (Qu et al 1995). Clini-
cal trials using HupA plus nilestriol (Wang et al 2003), or 
HupA plus nicergoline, aspirin as well as estrogen (Zhou et Clinical Interventions in Aging 2007:2(2) 203
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al 2004), have shown favorable results in both AD and VD 
patients. Clinical investigators also found that combination 
with function convalescence training, daily life activities 
training, or a speciﬁ  c mental stimulation program consisting 
of reminiscence, reality orientation and remotivation, can 
promote the effects of medicine treatment.
AD is a neurodegenerative disease with complicated 
pathogenesis, therefore therapy with multiple drugs or drugs 
with polypharmacological activities will likely be the best 
approache to address the varied pathological aspects of the 
disease. Encouraging preclinical and clinical ﬁ  ndings sug-
gest that HupA is a promising candidate for the treatment 
of neurodegenerative diseases such as AD and VD, and is 
very likely to exert its therapeutic effects via a multi-target 
mechanism.
Ginkgo biloba extract
Ginkgo biloba (Ginkgoaceae) is an ancient Chinese tree that 
has been cultivated and held sacred for its health-promoting 
properties. There is substantial experimental evidence to 
support the view that the leaf extract of Ginkgo biloba (EGb) 
has many pharmacological effects (Sierpina et al 2003). 
Pharmacological studies demonstrated that EGb can reverse 
yohimbine-induced spatial working memory deﬁ  cit in rats 
(Zhang and Cai 2005), improve learning performance in 
cerebral ischemic mice (Tadano et al 1998), reduces infarct 
volume and cell apoptosis in cortex of ischemic mice (Unal 
et al 2001), as well as reverse memory deﬁ  cit and decline 
in choline actyltransferase activities in the hippocampus of 
rats infused intracerebroventricularly with Aβ1–40 (Tang et al 
2002). In vitro studies showed that EGb can protect against 
apoptosis induced by hydroxyl radicals (Ni et al 1996; Wei 
et al 2000), against cell death induced by beta-amyloid (Bas-
tianetto et al 2000a), and against nitric oxide-induced toxic-
ity (Bastianetto et al 2000b). Mechanisms underlying these 
protective effects remain unclear. As we now know, EGb is 
a mixture of ﬂ  avonoids, terpenes, and organic acids, etc. EGb 
and its constituent ginkgolide B were reported to attenuate 
glutamate-induced neuronal damage (Zhu et al 1997). EGb’s 
ability to decrease bax/bcl-2 ratios (Lu et al 2006), reverse 
ischemia-induced reductions in COX III mRNA in CA1 
neurons prior to their death (Chandrasekaran et al 2001), 
inhibit nitric oxide synthesis (Calapai et al 2000), scavenge 
free radicals (Maitra et al 1995) and attenuate lipid peroxida-
tion (Bridi et al 2001) might involve in its neuroprotective 
effects. A very recent study suggests that EGb has potent 
antioxidant activity and may play a role in the neuroprotec-
tive process by attenuating the ischemia/reperfusion-induced 
oxidative protein modiﬁ  cation and lipoperoxidation (Urikova 
et al 2006).
Along with the progress in pharmacological research, 
quite a few preparations of EGb have been developed and put 
into home and overseas market during recent years. At pres-
ent EGb is used clinically for improving peripheral vascular 
diseases in France and Germany and is ingested widely as an 
herbal medicine in some countries. Double-blinded random-
ized controlled clinical trial has demonstrated the efﬁ  cacy of 
EGb 761, the standardized preparation of EGb, in treatment 
for mild to moderate AD (Maurer et al 1997). A 24-week, 
multicenter, double-blind, placebo-controlled, randomized 
trial conﬁ  rmed that EGb 761 improves cognitive function 
in a clinically relevant manner in patients suffering from de-
mentia (Kanowski and Hoerr 2003). Moreover, a very recent 
randomized placebo-controlled double-blind study showed 
that EGb 761 (160 mg/d) had a comparable efﬁ  cacy with 
donepezil (5 mg/d) in treating mild to moderate AD, and also 
suggested the efﬁ  cacy and tolerability of the Ginkgo biloba 
special extract (Flavogin) in the dementia of the Alzheimer 
type with special respect to moderately severe stages (Mazza 
et al 2006). Results from clinical trials in China demonstrated 
that treatment with EGb can signiﬁ  cantly improve the cogni-
tive function and living ability of patients with VD (Li 2003; 
Zhang and Li 2003; Shi et al 2006), multi-infarct dementia 
(Wu et al 2001), and cerebral infarction dementia (Wu 2003). 
Moreover, the active component of EGb, such as ginkgo 
ﬂ  avone glycoside, was also reported to be efﬁ  cient and safe 
for VD treatment (Li et al 2004a).
Radix ginseng
As a well known invigorant, there has been a long history 
of ginseng (Figure 1B) application in China. Its active com-
pounds, including total ginsenosides, ginsenoside Rg1, and 
panaxynol, were found to possess central cholinomimetic and 
catecholaminomimetic activity, and can modulate the balance 
of stimulating and inhibiting process in central nervous sys-
tem as well as promote neuronal plasticity and neurogenesis. 
Researchers found that ginsenosides Rb1 and Rg3 exerted 
signiﬁ  cant neuroprotective effects on cultured cortical cells 
against glutamate-induced neurodegeneration (Kim et al 
1998), indicating it may be efﬁ  cacious in protecting neurons 
from oxidative damage produced by exposure to excess glu-
tamate. Furthermore, protopanaxadiol-type saponins were 
reported to enhance axonal and dendritic formation activity 
(Tohda et al 2002). Pharmacological studies have demon-
strated that saponins can improve learning and memory in 
animals impaired with scopolamine (Ni et al 2000; Zhao et al Clinical Interventions in Aging 2007:2(2) 204
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2000; Chen and Zhu 2005) and transient global ischemia 
(Shen and Zhang 2004), as well as protect brain function and 
postpone brain aging by decreasing free radicals damage and 
increasing activities of GSH-Px and SOD (Zhang et al 2003). 
The ability of ginsenoside to enhance TrkB expression might 
also be involved in its protective effect (Lai et al 2006). Using 
3H-(-)nicotine displacement assay, Panax ginseng was found 
to have afﬁ  nity for both the nicotinic receptor, and to a lesser 
extent the muscarinic receptor (IC50 2.12 mg/mL and 5.25 
mg/mL respectively), and the activity of the plant extracts 
was excluded as resulting from choline (Lewis et al 1999), 
and the demonstrated nicotinic activity of ginseng warrants 
further investigation with reference to therapeutic activity in 
age-related conditions such as dementia.
Rhizoma anemarrhenae (Zhimu)
Rhizoma anemarrhenae (Figure 1C) is a commonly used 
medicinal material for nourishment. The main active 
constituents include sarsasapogenin, smilagenin, neogi-
togenin, and markosapogenin. Pharmacological studies 
demonstrated that it can protect from learning and memory 
impairment induced by D-galactose (Chen et al 2000; Ma 
et al 2004), scopolamine, AlCl3 (Ma et al 2005), β-amyloid 
peptide (Chen et al 2001a; Ouyang et al 2005), ibotenic 
acid (Sun et al 2004), cholesteremia and ischemic brain 
injury (Deng et al 2005), and enhance memory of normal 
aged animals (Hu et al 2003). These effects are very likely 
related with its activity of improving the synthetic speed 
of acetylcholine (ACh) and density of M-type ACh recep-
tors (Chen et al 2001b, 2004; Hu et al 2001), scavenging 
free radicals (Chen et al 2000), upregulating brain-derived 
neurotrophic factor (BDNF) (Hu et al 2003), as well as 
antioxidation (Ouyang et al 2005).
Integripetal rhodiola herb (Rhodiola 
rosea L.)
Integripetal rhodiola herb (Figure 1D) is a perennial plant 
of Rhodiola family with succulent rhizome. The essential 
component, rhodosin, is well known for protection against 
hypoxia and external injury. Recent studies have found that 
rhodosin or the crude extract can protect from learning and 
memory impairment induced by D-galactose (Xie et al 2003), 
scopolamine (Wu et al 2004b), β-amyloid peptide (Xie et al 
2004), hypoxia (Liu et al 2003), and cerebral ischemia-
reperfusion (Song et al 2005). Rhodosin can also enhance 
memory of normal-aged rats (Jiang et al 2001). Its ability to 
increase ACh content and reduce cholinesterase activity in 
the brain (Wu et al 2004b) and antioxidation activity (Jiang 
et al 2001) might contribute to preventing neurodegenera-
tive changes.
Danshen root (Salvia miltiorrhiza Bunge.)
Danshen root (Figure 1E) is a kind of medical material with 
activity of blood ﬂ  ow promotion and blood-stasis elimina-
tion, which has been frequently used for cardiovascular and 
hematological disorders in China. One of its constituent, 
namely tanshinone, can improve cholinergic functions in cen-
tral nervous system (Li et al 2004b) and inhibit inﬂ  ammatory 
reaction by inhibiting the expression of pro-inﬂ  ammatory 
cytokines (Hu et al 2006) and inducible nitrogen oxidase 
(iNOS) (Li et al 2004b). Salvianolic acid, another essential 
component, is an antioxidant (Huang and Zhang 1992) found 
to protect from ischemic brain injury (Wu et al 2000).
Radix puerariae (Pueraria lobata [Willd.] 
Ohwi)
Various medical properties of Radix puerariae (Figure 1F) 
have been documented over 2000 years. Flavone extracted 
from its radix and leaves are found to be of multiple health 
beneﬁ  ts. The active component, puerarin, proved to widen 
coronary artery and cerebral artery and help lower blood 
pressure. Recent studies revealed that puerarin can protect from 
learning and memory impairment induced by D-galactose (Xu 
and Zhao 2002), scopolamine (Hsieh et al 2002), β-amyloid 
peptide (Yang et al 2005), ischemic brain injury (Wu et al 
2004a), and chronic alcoholism (Sun 2005).
Green tea
The history of cultivating and drinking green tea in China 
is centuries old. Green tea is a popular beverage and is now 
widely believed to promote blood ﬂ  ow, lower blood fat, 
and help weight-loss. Recently, dietary components with 
antioxidant activity have attracted particular attention for 
their potential role in modulating oxidative stress associated 
with aging and chronic conditions. Consistent with epidemio-
logical studies, recent research indicates that the antioxidant 
properties of polyphenols, the active components enriched 
in green tea, may contribute to reducing the risk of cardio-
vascular disease, cancer, and dementia (Yan and Wu 2001; 
Li et al 2006), which are the leading causes of morbidity and 
mortality among the elderly (Meydani 2001). The in vitro 
anti-beta-secretase and dual anticholinesterase activities of 
green tea was reported recently, indicating that tea contains 
active agents, which may function synergistically, to retard Clinical Interventions in Aging 2007:2(2) 205
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progression of the diseases, assuming that these agents, yet 
to be identiﬁ  ed, reach the brain (Okello et al 2004).
Clinical studies
Though the term “senile dementia” did not appear in the 
traditional Chinese medical literature, ancient medics were 
conscious of the phenomena and depicted elaborately its 
clinic exhibitions in medical books, including memory 
letdown, vacant face expression, lack of responsiveness 
and decline of intellectual ability such as comprehension 
and judgment, as well as emotional abnormity. Over 
2000 years before, there were remarks of dementia and 
forgetfulness in the oldest medical book in China, Huang 
Di’s Canon of Internal Medicine. With the development 
of modern medicine, people are more acquainted with 
dementia. More and more new therapeutic programs are 
put forward and tested during the course of clinical prac-
tice, such as combination therapy using drugs of different 
pharmacological profiles, or using drugs in combination 
with mental training.
Assisting therapy and prevention
Most patients with dementia are looked after by family in 
China. Therefore lifestyle can inﬂ  uence the efﬁ  cacy of clini-
cal therapy to a certain degree, and access to social guidance, 
consultants, and assistance can be of a large beneft to the 
dementia patient. More people are beginning to realize the 
importance of a regular and disciplined healthy lifestyle. The 
daily diet is acquiring accumulating attention for its poten-
tial inﬂ  uence on health condition. With the development of 
imageology and neuropsychology, diagnosis and classiﬁ  ca-
tion of dementia are becoming easier and more accurate. 
Patients with dementia now have access to more reasonable 
and scientiﬁ  c diagnosis, treatment, and nursing.
Summary
Chinese people have studied and fought with dementia for a 
long period of time. An immense experience and systematic 
theory of treating dementia has been accumulated during 
the long history of development of TCM. Nowadays part of 
the experience is still relevant. With the global application 
Figure 1 Pictures of Chinese herbs and the parts effective in treating dementia. A: Huperzia serrata (Qian Ceng Ta); B: Panax ginseng C.A. Mey. (Ginseng), drawn by Zeng Li Li; 
C: Anemarrhena asphodeloides Bunge. (Zhimu), drawn by Chun Quan Xu; D: Rhodiola saccharinensis A. Bor. (Integripetal rhodiola herb); E: Salvia miltiorrhiza Bunge. (Danshen), 
drawn by Zeng Li Li; F: Pueraria lobata (Willd.) Ohwi (Radix Puerariae), drawn by Zeng Li Li. Panels B, C, E, and F are from (Lou and Xiao 1995). Panel D is from (Zhu 1999).Clinical Interventions in Aging 2007:2(2) 206
Yan et al
of modern science and technology, more and more natural 
resources and products from TCM are being studied and 
recognized. The resources and experience of TCM will 
continue to play an important role in the ﬁ  ght against aging 
and dementia.
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